Thermo Fisher Scientific has unveiled plans to invest $82.5 million to expand operations and create 169 new jobs at its biologic drug substance manufacturing facility in St. Louis County, according to The St. Louis Economic Development Partnership, the Missouri Department of Economic Development and Ameren Missouri. The expanded facility will manufacture biologic drug substance products that treat a variety of chronic health conditions including cancers and other life-threatening diseases as well as COVID-19.
 
“We continue to invest in capabilities and capacity at our St. Louis site to support the needs of our clients and the patients they serve,” said Michel Lagarde, executive vice president, Thermo Fisher Scientific. “This new expansion will enable further innovation in biologics manufacturing to address the continued growth in important therapies and medicines. We look forward to our continued contribution to job creation and economic development in this region.”
 
Thermo Fisher’s current commercial biologics manufacturing footprint in St. Louis is 360,000 square feet with approximately 700 employees. The new project will include a 58,000-square-foot expansion with two new manufacturing suites and the addition of nearly $15 million in new manufacturing machinery and equipment over a two-year period, including the new ability to provide manufacturing and production support at both the 5,000-Liter processing scale as well as continued support at the 2,000-Liter processing scale. The addition is facilitated by local tax incentives, including a 10-year new project abatement beginning in 2024.